Molecular mechanisms and clinical implications of miRNAs in drug resistance of esophageal cancer

References

• Domper AM, Ferrandez AA, Lanas AA. Esophageal cancer: risk factors, screening and endoscopic treatment in Western and Eastern countries. World J Gastroenterol. 2015;21:7933–7943.
   PubMed Web of Science ®Google Scholar
• Chen WQ, Zheng RS, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–132.
   PubMed Web of Science ®Google Scholar
• Arnold M, Soerjomataram I, Ferlay J, et al. Global incidence of oesophageal cancer by histological subtype in 2012. Gut. 2015;64:381–387.
   PubMed Web of Science ®Google Scholar
• Siewert JR, Ott K. Are squamous and adenocarcinomas of the esophagus the same disease? Semin Radiat Oncol. 2007;17:38–44.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network; Analysis Working Group: Asan University; BC Cancer Agency, et al. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017;541:169–175.
   PubMed Web of Science ®Google Scholar
• Kuwano H, Saeki H, Kawaguchi H, et al. Proliferative activity of cancer cells in front and center areas of carcinoma in situ and invasive sites of esophageal squamous-cell carcinoma. Int J Cancer. 1998;78:149–152.
   PubMed Web of Science ®Google Scholar
• Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst. 2008;100:1184–1187.
   PubMed Web of Science ®Google Scholar
• Rubenstein JH, Shaheen NJ. Epidemiology, diagnosis, and management of esophageal adenocarcinoma. Gastroenterology. 2015;149:302–317.
   PubMed Web of Science ®Google Scholar
• Pennathur A, Gibson MK, Jobe BA, et al. Oesophageal carcinoma. Lancet. 2013;381:400–412.
   PubMed Web of Science ®Google Scholar
• Hong L, Han Y, Lu Q, et al. Drug resistance-related microRNAs in esophageal cancer. Expert Opin Biol Ther. 2012;12:1487–1494.
   PubMed Web of Science ®Google Scholar
• An X, Sarmiento C, Tan T, et al. Regulation of multidrug resistance by microRNAs in anti-cancer therapy. Acta Pharm Sin B. 2017;7:38–51.
   PubMed Web of Science ®Google Scholar
• Gong J, Jaiswal R, Mathys JM, et al. Microparticles and their emerging role in cancer multidrug resistance. Cancer Treat Rev. 2012;38:226–234.
   PubMed Web of Science ®Google Scholar
• Sakai NS, Samia-Aly E, Barbera M, et al. A review of the current understanding and clinical utility of miRNAs in esophageal cancer. Semin Cancer Biol. 2013;23:512–521.
   PubMed Web of Science ®Google Scholar
• Qin Q, Wei F, Li B. Multiple functions of hypoxia-regulated miR-210 in cancer. J Exp Clin Cancer. 2014;33:50.
   PubMed Web of Science ®Google Scholar
• Hong L, Han Y, Zhang Y, et al. MicroRNA-21: a therapeutic target for reversing drug resistance in cancer. Expert Opin Ther Tar. 2013;17:1073–1080.
   PubMed Web of Science ®Google Scholar
• David S, Meltzer SJ. MicroRNA involvement in esophageal carcinogenesis. Curr Opin Pharmacol. 2011;11:612–616.
   PubMed Web of Science ®Google Scholar
• Hong L, Yang Z, Ma J, et al. Function of miRNA in controlling drug resistance of human cancers. Curr Drug Targets. 2013;14:1118–1127.
   PubMed Web of Science ®Google Scholar
• Liang H, Gong F, Zhang S, et al. The origin, function, and diagnostic potential of extracellular microRNAs in human body fluids. Wiley Interdiscip Rev RNA. 2014;5:285–300.
   PubMed Web of Science ®Google Scholar
• Song JH, Meltzer SJ. MicroRNAs in pathogenesis, diagnosis, and treatment of gastroesophageal cancers. Gastroenterology. 2012;143:35–47.
   PubMed Web of Science ®Google Scholar
• Tong YA, Peng H, Zhan C, et al. Genome-wide analysis reveals diversity of rice intronic miRNAs in sequence structure, biogenesis and function. Plos One. 2013;8:e63938.
   PubMed Web of Science ®Google Scholar
• Lee H, Han S, Kwon CS, et al. Biogenesis and regulation of the let-7 miRNAs and their functional implications. Protein Cell. 2016;7:100–113.
   PubMed Web of Science ®Google Scholar
• Dangwal S, Thum T. MicroRNAs in platelet biogenesis and function. Thromb Haemost. 2012;108:599–604.
   PubMed Web of Science ®Google Scholar
• Huang X, Le QT, Giaccia AJ. MiR-210–micromanager of the hypoxia pathway. Trends Mol Med. 2010;16:230–237.
   PubMed Web of Science ®Google Scholar
• Giraldez AJ, Mishima Y, Rihel J, et al. Zebrafish MiR-430 promotes deadenylation and clearance of maternal mRNAs. Science. 2006;312:75–79.
   PubMed Web of Science ®Google Scholar
• Peters L, Meister G. Argonaute proteins: mediators of RNA silencing. Mol Cell. 2007;26:611–623.
   PubMed Web of Science ®Google Scholar
• Chua JH, Armugam A, Jeyaseelan K. MicroRNAs: biogenesis, function and applications. Curr Opin Mol Ther. 2009;11:189–199.
   PubMed Web of Science ®Google Scholar
• Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 2010;11:597–610.
   PubMed Web of Science ®Google Scholar
• Lytle JR, Yario TA, Steitz JA. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5ʹ UTR as in the 3ʹ UTR. Proc Natl Acad Sci U S A. 2007;104:9667–9672.
   PubMed Web of Science ®Google Scholar
• Hong L, Han Y, Zhang H, et al. Prognostic markers in esophageal cancer: from basic research to clinical use. Expert Rev Gastroenterol Hepatol. 2015;9:887–889.
   PubMed Web of Science ®Google Scholar
• Haenisch S, Cascorbi I. miRNAs as mediators of drug resistance. Epigenomics-Uk. 2012;4:369–381.
   PubMed Web of Science ®Google Scholar
• Berman M, Mattheolabakis G, Suresh M, et al. Reversing epigenetic mechanisms of drug resistance in solid tumors using targeted microRNA delivery. Expert Opin Drug Deliv. 2016;13:987–998.
   PubMed Web of Science ®Google Scholar
• Mishra PJ, Humeniuk R, Mishra PJ, et al. A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc Natl Acad Sci U S A. 2007;104:13513–13518.
   PubMed Web of Science ®Google Scholar
• Gong JP, Yang L, Tang JW, et al. Overexpression of microRNA-24 increases the sensitivity to paclitaxel in drug-resistant breast carcinoma cell lines via targeting ABCB9. Oncol Lett. 2016;12:3905–3911.
   PubMed Web of Science ®Google Scholar
• Hemmatzadeh M, Mohammadi H, Karimi M, et al. Differential role of microRNAs in the pathogenesis and treatment of esophageal cancer. Biomed Pharmacother. 2016;82:509–519.
   PubMed Web of Science ®Google Scholar
• Wu K, Yang Y, Zhao J, et al. BAG3-mediated miRNA let-7g and let-7i inhibit proliferation and enhance apoptosis of human esophageal carcinoma cells by targeting the drug transporter ABCC10. Cancer Lett. 2016;371:125–133.
   PubMed Web of Science ®Google Scholar
• Meng F, Qian L, Lv L, et al. miR-193a-3p regulation of chemoradiation resistance in oesophageal cancer cells via the PSEN1 gene. Gene. 2016;579:139–145.
   PubMed Web of Science ®Google Scholar
• Ma J, Hong L, Xu G, et al. miR-483-3p plays an oncogenic role in esophageal squamous cell carcinoma by targeting tumor suppressor EI24. Cell Biol Int. 2016;40:448–455.
   PubMed Web of Science ®Google Scholar
• Nyhan MJ, O’Donovan TR, Boersma AW, et al. MiR-193b promotes autophagy and non-apoptotic cell death in oesophageal cancer cells. BMC Cancer. 2016;16:101.
   PubMed Web of Science ®Google Scholar
• Jin YY, Chen QJ, Xu K, et al. Involvement of microRNA-141-3p in 5-fluorouracil and oxaliplatin chemo-resistance in esophageal cancer cells via regulation of PTEN. Mol Cell Biochem. 2016;422:161–170.
   PubMed Web of Science ®Google Scholar
• Tanaka K, Miyata H, Sugimura K, et al. miR-27 is associated with chemoresistance in esophageal cancer through transformation of normal fibroblasts to cancer-associated fibroblasts. Carcinogenesis. 2015;36:894–903.
   PubMed Web of Science ®Google Scholar
• Fujiwara N, Inoue J, Kawano T, et al. miR-634 activates the mitochondrial apoptosis pathway and enhances chemotherapy-induced cytotoxicity. Cancer Res. 2015;75:3890–3901.
   PubMed Web of Science ®Google Scholar
• Bibby BA, Reynolds JV, Maher SG. MicroRNA-330-5p as a putative modulator of neoadjuvant chemoradiotherapy sensitivity in oesophageal adenocarcinoma. Plos One. 2015;10:e134180.
   Web of Science ®Google Scholar
• Xia H, Chen S, Chen K, et al. MiR-96 promotes proliferation and chemo- or radioresistance by down-regulating RECK in esophageal cancer. Biomed Pharmacother. 2014;68:951–958.
   PubMed Web of Science ®Google Scholar
• Hummel R, Watson DI, Smith C, et al. Mir-148a improves response to chemotherapy in sensitive and resistant oesophageal adenocarcinoma and squamous cell carcinoma cells. J Gastrointest Surg. 2011;15:429–438.
   PubMed Web of Science ®Google Scholar
• Zhang H, Li M, Han Y, et al. Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma. Dig Dis Sci. 2010;55:2545–2551.
   PubMed Web of Science ®Google Scholar
• Hong L, Han Y, Zhang H, et al. The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma. Ann Surg. 2010;251:1056–1063.
   PubMed Web of Science ®Google Scholar
• Imanaka Y, Tsuchiya S, Sato F, et al. MicroRNA-141 confers resistance to cisplatin-induced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma. J Hum Genet. 2011;56:270–276.
   PubMed Web of Science ®Google Scholar
• Hamano R, Miyata H, Yamasaki M, et al. Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway. Clin Cancer Res. 2011;17:3029–3038.
   PubMed Web of Science ®Google Scholar
• Sugimura K, Miyata H, Tanaka K, et al. Let-7 expression is a significant determinant of response to chemotherapy through the regulation of IL-6/STAT3 pathway in esophageal squamous cell carcinoma. Clin Cancer Res. 2012;18:5144–5153.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Hong L. Prediction value of miR-483 and miR-214 in prognosis and multidrug resistance of esophageal squamous cell carcinoma. Genet Test Mol Biomarkers. 2013;17:470–474.
   PubMed Web of Science ®Google Scholar
• Derouet MF, Liu G, Darling GE. MiR-145 expression accelerates esophageal adenocarcinoma progression by enhancing cell invasion and anoikis resistance. Plos One. 2014;9:e115589.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhao Y, Herbst A, et al. miR-221 mediates chemoresistance of esophageal adenocarcinoma by direct targeting of DKK2 expression. Ann Surg. 2016;264:804–814.
   PubMed Web of Science ®Google Scholar
• Tian J, Shang M, Shi SB, et al. Cetuximab plus pemetrexed as second-line therapy for fluorouracil-based pre-treated metastatic esophageal squamous cell carcinoma. Cancer Chemother Pharmacol. 2015;76:829–834.
   PubMed Web of Science ®Google Scholar
• Ko MA, Zehong G, Virtanen C, et al. MicroRNA expression profiling of esophageal cancer before and after induction chemoradiotherapy. Ann Thorac Surg. 2012;94:1094-1102,1102-1103.
   Web of Science ®Google Scholar
• Komatsu S, Ichikawa D, Kawaguchi T, et al. Circulating miR-21 as an independent predictive biomarker for chemoresistance in esophageal squamous cell carcinoma. Am J Cancer Res. 2016;6:1511–1523.
   PubMed Web of Science ®Google Scholar
• Komatsu S, Ichikawa D, Kawaguchi T, et al. Plasma microRNA profiles: identification of miR-23a as a novel biomarker for chemoresistance in esophageal squamous cell carcinoma. Oncotarget. 2016;7:62034–62048.
   PubMed Web of Science ®Google Scholar
• Chen G, Peng J, Zhu W, et al. Combined downregulation of microRNA-133a and microRNA-133b predicts chemosensitivity of patients with esophageal squamous cell carcinoma undergoing paclitaxel-based chemotherapy. Med Oncol. 2014;31:263.
   PubMed Web of Science ®Google Scholar
• Tian H, Hou L, Xiong YM, et al. miR-218 suppresses tumor growth and enhances the chemosensitivity of esophageal squamous cell carcinoma to cisplatin. Oncol Rep. 2015;33:981–989.
   PubMed Web of Science ®Google Scholar
• Ichikawa D, Komatsu S, Konishi H, et al. Circulating microRNA in digestive tract cancers. Gastroenterology. 2012;142:1074–1078.
   PubMed Web of Science ®Google Scholar
• Dang K, Myers K. The role of hypoxia-induced miR-210 in cancer progression. Int J Mol Sci. 2015;16:6353–6372.
   PubMed Web of Science ®Google Scholar
• Hummel R, Sie C, Watson DI, et al. MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol. 2014;20:14904–14912.
   PubMed Web of Science ®Google Scholar
• Lindner K, Borchardt C, Schopp M, et al. Proton pump inhibitors (PPIs) impact on tumour cell survival, metastatic potential and chemotherapy resistance, and affect expression of resistance-relevant miRNAs in esophageal cancer. J Exp Clin Cancer Res. 2014;33:73.
   PubMed Web of Science ®Google Scholar
• Amin M, Lam AK. Current perspectives of mi-RNA in oesophageal adenocarcinoma: roles in predicting carcinogenesis, progression and values in clinical management. Exp Mol Pathol. 2015;98:411–418.
   PubMed Web of Science ®Google Scholar
• Lynam-Lennon N, Reynolds JV, Marignol L, et al. MicroRNA-31 modulates tumour sensitivity to radiation in oesophageal adenocarcinoma. J Mol Med (Berl). 2012;90:1449–1458.
   PubMed Web of Science ®Google Scholar
• Van Baal JW, Verbeek RE, Bus P, et al. microRNA-145 in Barrett’s oesophagus: regulating BMP4 signalling via GATA6. Gut. 2013;62:664–675.
   PubMed Web of Science ®Google Scholar
• Dehghanzadeh R, Jadidi-Niaragh F, Gharibi T, et al. MicroRNA-induced drug resistance in gastric cancer. Biomed Pharmacother. 2015;74:191–199.
   PubMed Web of Science ®Google Scholar
• Thomas S, Quinn BA, Das SK, et al. Targeting the Bcl-2 family for cancer therapy. Expert Opin Ther Targets. 2013;17:61–75.
   PubMed Web of Science ®Google Scholar
• He Z, Yu L, Luo S, et al. miR-296 inhibits the metastasis and epithelial-mesenchymal transition of colorectal cancer by targeting S100A4. BMC Cancer. 2017;17:140.
   PubMed Web of Science ®Google Scholar
• Riquelme I, Letelier P, Riffo-Campos AL, et al. Emerging role of miRNAs in the drug resistance of gastric cancer. Int J Mol Sci. 2016;17:424.
   PubMed Web of Science ®Google Scholar
• Lim HJ, Crowe P, Yang JL. Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer. J Cancer Res Clin Oncol. 2015;141:671–689.
   PubMed Web of Science ®Google Scholar
• Mutlu M, Raza U, Saatci O, et al. miR-200c: a versatile watchdog in cancer progression, EMT, and drug resistance. J Mol Med (Berl). 2016;94:629–644.
   PubMed Web of Science ®Google Scholar
• Wera S, Fernandez A, Lamb NJ, et al. Deregulation of translational control of the 65-kDa regulatory subunit (PR65 alpha) of protein phosphatase 2A leads to multinucleated cells. J Biol Chem. 1995;270:21374–21381.
   PubMed Web of Science ®Google Scholar
• Lu J, Kovach JS, Johnson F, et al. Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms. Proc Natl Acad Sci U S A. 2009;106:11697–11702.
   PubMed Web of Science ®Google Scholar
• Gao Y, Feng B, Han S, et al. The roles of microRNA-141 in human cancers: from diagnosis to treatment. Cell Physiol Biochem. 2016;38:427–448.
   PubMed Web of Science ®Google Scholar
• Lee KH, Chen YL, Yeh SD, et al. MicroRNA-330 acts as tumor suppressor and induces apoptosis of prostate cancer cells through E2F1-mediated suppression of Akt phosphorylation. Oncogene. 2009;28:3360–3370.
   PubMed Web of Science ®Google Scholar
• Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal. 2002;14:381–395.
   PubMed Web of Science ®Google Scholar
• Xin SY, Feng XS, Zhou LQ, et al. Reduced expression of circulating microRNA-218 in gastric cancer and correlation with tumor invasion and prognosis. World J Gastroenterol. 2014;20:6906–6911.
   PubMed Web of Science ®Google Scholar
• Li J, Ping Z, Ning H. MiR-218 impairs tumor growth and increases chemo-sensitivity to cisplatin in cervical cancer. Int J Mol Sci. 2012;13:16053–16064.
   PubMed Web of Science ®Google Scholar
• Ahmed K, Tabuchi Y, Kondo T. Hyperthermia: an effective strategy to induce apoptosis in cancer cells. Apoptosis. 2015;20:1411–1419.
   PubMed Web of Science ®Google Scholar
• Mohammad RM, Muqbil I, Lowe L, et al. Broad targeting of resistance to apoptosis in cancer. Semin Cancer Biol. 2015;35 Suppl:S78–S103.
   PubMed Web of Science ®Google Scholar
• Strano S, Monti O, Pediconi N, et al. The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA Damage. Mol Cell. 2005;18:447–459.
   PubMed Web of Science ®Google Scholar
• Shimizu S, Yoshida T, Tsujioka M, et al. Autophagic cell death and cancer. Int J Mol Sci. 2014;15:3145–3153.
   PubMed Web of Science ®Google Scholar
• Paoli P, Giannoni E, Chiarugi P. Anoikis molecular pathways and its role in cancer progression. Biochim Biophys Acta. 2013;1833:3481–3498.
   PubMed Web of Science ®Google Scholar
• Cuadros T, Trilla E, Sarro E, et al. HAVCR/KIM-1 activates the IL-6/STAT-3 pathway in clear cell renal cell carcinoma and determines tumor progression and patient outcome. Cancer Res. 2014;74:1416–1428.
   PubMed Web of Science ®Google Scholar
• Mukherjee A, Khuda-Bukhsh AR. Quercetin down-regulates IL-6/STAT-3 signals to induce mitochondrial-mediated apoptosis in a nonsmall-cell lung-cancer cell line, A549. J Pharmacopuncture. 2015;18:19–26.
   PubMed Web of Science ®Google Scholar
• Holohan C, Van Schaeybroeck S, Longley DB, et al. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13:714–726.
   PubMed Web of Science ®Google Scholar
• Giovannetti E, Erozenci A, Smit J, et al. Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. Crit Rev Oncol Hematol. 2012;81:103–122.
   PubMed Web of Science ®Google Scholar
• Kartner N, Riordan JR, Ling V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science. 1983;221:1285–1288.
   PubMed Web of Science ®Google Scholar
• Kunjachan S, Rychlik B, Storm G, et al. Multidrug resistance: physiological principles and nanomedical solutions. Adv Drug Deliv Rev. 2013;65:1852–1865.
   PubMed Web of Science ®Google Scholar
• Kathawala RJ, Gupta P, Ashby CJ, et al. The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade. Drug Resist Updat. 2015;18:1–17.
   PubMed Web of Science ®Google Scholar
• Johnson CD, Esquela-Kerscher A, Stefani G, et al. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res. 2007;67:7713–7722.
   PubMed Web of Science ®Google Scholar
• Lan FF, Wang H, Chen YC, et al. Hsa-let-7g inhibits proliferation of hepatocellular carcinoma cells by downregulation of c-Myc and upregulation of p16 (INK4A). Int J Cancer. 2011;128:319–331.
   PubMed Web of Science ®Google Scholar
• Hong KJ, Hsu MC, Hung WC. RECK impedes DNA repair by inhibiting the erbB/JAB1/Rad51 signaling axis and enhances chemosensitivity of breast cancer cells. Am J Cancer Res. 2015;5:2422–2430.
   PubMed Web of Science ®Google Scholar
• Zhao L, Liu W, Xiao J, et al. The role of exosomes and “exosomal shuttle microRNA” in tumorigenesis and drug resistance. Cancer Lett. 2015;356:339–346.
   PubMed Web of Science ®Google Scholar
• Chiam K, Wang T, Watson DI, et al. Circulating serum exosomal miRNAs as potential biomarkers for esophageal adenocarcinoma. J Gastrointest Surg. 2015;19:1208–1215.
   PubMed Web of Science ®Google Scholar
• Zhou X, Wen W, Zhu J, et al. A six-microRNA signature in plasma was identified as a potential biomarker in diagnosis of esophageal squamous cell carcinoma. Oncotarget. 2017;8:34468–34480.
   PubMed Web of Science ®Google Scholar
• Liao J, Liu R, Shi YJ, et al. Exosome-shuttling microRNA-21 promotes cell migration and invasion-targeting PDCD4 in esophageal cancer. Int J Oncol. 2016;48:2567–2579.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Kamohara H, Kinoshita K, et al. Clinical impact of serum exosomal microRNA-21 as a clinical biomarker in human esophageal squamous cell carcinoma. Cancer-Am Cancer Soc. 2013;119:1159–1167.
   PubMedGoogle Scholar
• Tokarz P, Blasiak J. The role of microRNA in metastatic colorectal cancer and its significance in cancer prognosis and treatment. Acta Biochim Pol. 2012;59:467–474.
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Inoue J, Kawano T, et al. The impact of miRNA-based molecular diagnostics and treatment of NRF2-stabilized tumors. Mol Cancer Res. 2014;12:58–68.
   PubMed Web of Science ®Google Scholar